

## Datasheet: MCA2520F

|                      |                             |
|----------------------|-----------------------------|
| <b>Description:</b>  | MOUSE ANTI HUMAN CD65s:FITC |
| <b>Specificity:</b>  | CD65s                       |
| <b>Other names:</b>  | CDw65                       |
| <b>Format:</b>       | FITC                        |
| <b>Product Type:</b> | Monoclonal Antibody         |
| <b>Clone:</b>        | VIM-2                       |
| <b>Isotype:</b>      | IgM                         |
| <b>Quantity:</b>     | 0.1 mg                      |

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|                | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | ■   |    |                | neat - 1/10        |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

|                                |                                                                                                    |                     |                   |
|--------------------------------|----------------------------------------------------------------------------------------------------|---------------------|-------------------|
| Target Species                 | Human                                                                                              |                     |                   |
| Product Form                   | Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid                     |                     |                   |
| Max Ex/Em                      | Fluorophore                                                                                        | Excitation Max (nm) | Emission Max (nm) |
|                                | FITC                                                                                               | 490                 | 525               |
| Preparation                    | Purified IgM prepared by ammonium sulphate precipitation.                                          |                     |                   |
| Buffer Solution                | Phosphate buffered saline                                                                          |                     |                   |
| Preservative                   | 0.09% Sodium Azide (NaN <sub>3</sub> )                                                             |                     |                   |
| Stabilisers                    | 1% Bovine Serum Albumin                                                                            |                     |                   |
| Approx. Protein Concentrations | IgM concentration 0.1mg/ml                                                                         |                     |                   |
| Immunogen                      | THP1 (human acute monocytic leukaemia cells)                                                       |                     |                   |
| Fusion Partners                | Spleen cells from immunised Balb/c mice were fused with cells of the mouse NS-1 myeloma cell line. |                     |                   |
| Specificity                    | Mouse anti Human CD65s antibody, clone VIM-2 selectively recognizes the sialylated form of         |                     |                   |

human CD65, known as CD65s (VIM-2 antigen), a leucocyte carbohydrate antigen expressed by granulocytes, monocytes and leukaemic cells of myelomonocytic lineage.

CD65s is aberrantly expressed on some acute myeloid leukaemias (AML) and clone VIM-2 has been reliably used as a marker for distinguishing between mature and undifferentiated AML. During normal myelopoiesis, expression of CD65s follows the disappearance of the progenitor antigen CD34.

Cross-linking of the CD65s antigen using clone VIM-2, has been shown to induce phagocyte cytoplasmic calcium flux, oxidative burst and degranulation ([Lund-Johansen et al. 1992](#)).

---

|                       |                                                                                     |
|-----------------------|-------------------------------------------------------------------------------------|
| <b>Flow Cytometry</b> | Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul. |
|-----------------------|-------------------------------------------------------------------------------------|

---

|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>References</b> | <ol style="list-style-type: none"><li>1. Gooi, H.C. <i>et al.</i> (1985) Differences in the fine specificities of monoclonal (Class A) antibodies to human myeloid cells. <a href="#">Clin Exp Immunol. 60 (1): 151-8.</a></li><li>2. Lund-johansen, F. <i>et al.</i> (1992) Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65). <a href="#">J Immunol. 148 (10): 3221-9.</a></li><li>3. Knapp, W. <i>et al.</i> (1994) Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. <a href="#">Cytometry. 18 (4): 187-98.</a></li><li>4. Lund-johansen, F. <i>et al.</i> (1990) Flow cytometric assay for the measurement of human bone marrow phenotype, function and cell cycle. <a href="#">Cytometry. 11 (5): 610-6.</a></li><li>5. Bengtson, P. <i>et al.</i> (2002) Polymorphonuclear Leukocytes from Individuals Carrying the G329A Mutation in the <math>\alpha</math>1,3-Fucosyltransferase VII Gene (FUT7) Roll on E- and P-Selectins <a href="#">J Immunol. 169: 3940-6.</a></li><li>6. Buffone, A. <i>et al.</i> (2013) Silencing <math>\alpha</math>1,3-fucosyltransferases in human leukocytes reveals a role for FUT9 during E-selectin mediated cell adhesion. <a href="#">J Biol Chem. 288: 1620-33.</a></li><li>7. Nakayama, F. <i>et al.</i> (2001) CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV. <a href="#">J Biol Chem. 276: 16100-6.</a></li><li>8. Rao, R.M. <i>et al.</i> (2001) The S128R polymorphism of E-selectin mediates neuraminidase-resistant tethering of myeloid cells under shear flow. <a href="#">Eur J Immunol. 32: 251-60.</a></li><li>9. Paietta, E. <i>et al.</i> (2003) Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. <a href="#">Leukemia. 17: 1544-50.</a></li><li>10. Bengtson, P. <i>et al.</i> (2001) Identification of a missense mutation (G329A;Arg(110)--&gt; GLN) in the human FUT7 gene. <a href="#">J Biol Chem. 276: 31575-82.</a></li><li>11. Oehler, L. <i>et al.</i> (1998) Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. <a href="#">J Exp Med. 187: 1019-28.</a></li></ol> |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

---

|                |                                                                                                                                                                                                                                                                                                                                                                               |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Storage</b> | Store at +4°C or at -20°C if preferred.<br>Storage in frost-free freezers is not recommended.<br>This product should be stored undiluted. This product is photosensitive and should be protected from light.<br>Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

---

|                   |                                  |
|-------------------|----------------------------------|
| <b>Shelf Life</b> | 18 months from date of despatch. |
|-------------------|----------------------------------|

---

|                                      |                                                                                                                                                                                                          |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Health And Safety Information</b> | Material Safety Datasheet documentation #10041 available at:<br>10041: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf</a> |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

---

|                   |                            |
|-------------------|----------------------------|
| <b>Regulatory</b> | For research purposes only |
|-------------------|----------------------------|

---

## Related Products

### Recommended Negative Controls

[MOUSE IgM NEGATIVE CONTROL:FITC \(MCA692F\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South  
America**

Tel: +1 800 265 7376

Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M301736:170109'

**Printed on 01 May 2018**

---

© 2018 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)